Hospital Pharmacy - July/August 2017 - 468

468
References
1. Beitz JG. NDA approval letter: symproic (naldemedine NDA
208854). Food and Drug Administration website. https://
www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/20
8854Orig1s000ltr.pdf. Published March 23, 2017. Accessed
March 25, 2017.
2. Symproic (naldemedine) [prescribing information]. Florham
Park, NJ: Shionogi Inc; March 2017.
3. Boku N, Katakami N, Fujita S, et al. A phase II randomized,
double-blind, placebo-controlled study to evaluate naldemedine for the treatment of opioid-induced constipation (OIC) in
patients with cancer pain. J Clin Oncol. 2015;33(15):abstract
9594.
4. Kolbow J, Modess C, Wegner D, et al. Extended-release but not
immediate-release and subcutaneous methylnaltrexone antagonizes the loperamide-induced delay of whole-gut transit time in
healthy subjects. J Clin Pharmacol. 2016;56(2):239-245.
5. Camilleri M. Opioid-induced constipation: challenges and
therapeutic opportunities. Am J Gastroenterol. 2011;106(5):
835-842.
6. Holder RM, Rhee D. Novel oral therapies for opioid-induced
bowel dysfunction in patients with chronic noncancer pain.
Pharmacotherapy. 2016;36(3):287-299.
7. Nelson AD, Camilleri M. Opioid-induced constipation:
advances and clinical guidance. Ther Adv Chronic Dis.
2016;7(2):121-134.
8. Fernandes AW, Kern DM, Datto C, Chen YW, McLeskey C,
Tunceli O. Increased burden of healthcare utilization and cost
associated with opioid-related constipation among patients with
noncancer pain. Am Health Drug Benefits. 2016;9(3):160-170.
9. Yuan CS, Foss JF, Osinski J, Toledano A, Roizen MF, Moss
J. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin
Pharmacol Ther. 1997;61(4):467-475.
10. Movantik (naloxegol) [prescribing information]. Wilmington,
DE: AstraZeneca Pharmaceuticals; October 2016.
11. Relistor (methylnaltrexone bromide) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; January 2017.
12. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN,
Tack J. Naloxegol for opioid-induced constipation in patients
with noncancer pain. N Engl J Med. 2014;370(25):2387-2396.
13. Kanemasa T, Koike K, Arai T, et al. Effects of naldemedine:
a peripherally acting mu-opioid receptor antagonist in rat
models of opioid-induced constipation. Am J Gastroenterol.
2015;110(suppl 1):S578:abstract 1322.
14. Yuan CS, Foss JF. Oral methylnaltrexone for opioid-induced
constipation. JAMA. 2000;284(11):1383-1384.
15. Amitiza (lubiprostone) capsules [prescribing information].
Deerfield, IL: Takeda Pharmaceuticals America Inc; September
2016.
16. Fukumura K, Yokota T, Baba Y, Ferreira JCA. Phase 1, randomized, double-blind, placebo-controlled studies of the
safety, tolerability and pharmacokinetics of naldemedine in
healthy volunteers. Gastroenterology. 2016;150(4)(suppl
1):S537-S538.
17. Chou R, Fanciullo GJ, Fine PG, et al; American Pain SocietyAmerican Academy of Pain Medicine Opioids Guidelines
Panel. Clinical guidelines for the use of chronic opioid therapy
in chronic noncancer pain. J Pain. 2009;10(2)113-130.

Hospital Pharmacy 52(7)
18. Ferreira JCA, Reddy J, Yamada T, Baba Y, Nagata T. A phase
3, randomized, double-blind, placebo-controlled study of
naldemedine for the treatment of opioid-induced constipation
(OIC) in patients with chronic noncancer pain receiving opioid therapy. Paper presented at the 2016 American Academy
of Pain Medicine Annual Meeting; February 18-21, 2016;
Palm Springs, CA. http://www.painmed.org/2016posters/
abstract-192/. Accessed September 15, 2016.
19. Hale ME, Wild J, Reddy J, Yamada T, Ferreira JCA. Efficacy
and safety of naldemedine for the treatment of opioid-induced
constipation in subjects with chronic non-cancer pain receiving opioid therapy: results from two phase 3 clinical trials.
Gastroenterology. 2016;150(4)(suppl 1):S121-S122.
20. Shionogi. Efficacy and safety of naldemedine in the treatment
of opioid-induced constipation. ClinicalTrials.gov website.
https://clinicaltrials.gov/ct2/show/NCT01965158. Published
May 5, 2016. Accessed September 13, 2016.
21. Shionogi. Efficacy and safety of naldemedine in treating opioid-induced constipation. ClinicalTrials.gov website. https://
clinicaltrials.gov/ct2/show/NCT01993940. Published May 5,
2016. Accessed September 13, 2016.
22. Shionogi. Two naldemedine phase III studies show consistent
improvement of opioid-induced constipation [news release].
http://www.prnewswire.com/news-releases/two-naldemedinephase-iii-studies-show-consistent-improvement-of-opioidinduced-constipation-300272018.html. Published May 23,
2016. Accessed September 15, 2016.
23. Webster LR, Yamada T, Ferreira JCA, Davidson J. A phase 2
randomized, double-blind, placebo-controlled study to evaluate
naldemedine for the treatment of opioid-induced constipation
in patients with chronic non-cancer pain. Gastroenterology.
2015;148(4)(suppl 1):S-1194.
24. Webster LR, Nagata T, Yamada T, Ferreira JCA. A phase
2a, randomized, double-blind, placebo-controlled, single
ascending-dose study to evaluate the safety and efficacy
of naldemedine in patients with chronic non-cancer pain
and opioid-induced bowel dysfunction. Gastroenterology.
2015;148(4)(suppl 1):S-94.
25. Webster L, Nalamachu S, Yamada T, Reddy J, Baba Y,
Ferreira JCA. Long-term safety and efficacy of naldemedine for the treatment of opioid-induced constipation
in subjects with chronic non-cancer pain receiving opioid therapy: results from a 52-week phase 3 clinical trial.
Postgrad Med J. 2016;128(suppl 2):5. doi:10.1080/003254
81.2016.1224633.
26. Shionogi. Long term safety of naldemedine. ClinicalTrials.
gov website. https://clinicaltrials.gov/ct2/show/NCT01965652.
Published May 5, 2016. Accessed September 13, 2016.
27. Migoya E, Fukumura K, Yamada T, Ferreira JA. Effect of
naldemedine, a peripherally acting mu-opioid receptor antagonist, on QT interval. J Pain. 2016;17(4):S81. doi:10.1016/j.
jpain.2016.01.403.
28. Shionogi. Shionogi announces acceptance of new drug application in the U.S. for naldemedine for the treatment of opioidinduced constipation [news release]. http://www.prnewswire.
com/news-releases/shionogi-announces-acceptance-of-newdrug-application-in-the-us-for-naldemedine-for-the-treatmentof-opioid-induced-constipation-300279579.html.
Published
June 6, 2016. Accessed September 2016.

http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208854Origls000ltr.pdf http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208854Origls000ltr.pdf http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208854Origls000ltr.pdf http://www.painmed.org/2016posters/abstract-192/ http://www.painmed.org/2016posters/abstract-192/ http://www.ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT01965158 http://www.ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT01993940 https://www.clinicaltrials.gov/ct2/show/NCT01993940 http://www.prnewswire.com/news-releases/two-naldemedine-phase-iii-studies-show-consistent-improvement-of-opioid-induced-constipation-300272018.html http://www.prnewswire.com/news-releases/two-naldemedine-phase-iii-studies-show-consistent-improvement-of-opioid-induced-constipation-300272018.html https://www.clinicaltrials.gov/ct2/show/NCT01965652 http://www.prnewswire.com/news-releases/shionogi-announces-acceptance-of-new-drug-application-in-the-us-for-naldemedine-for-the-treatment-of-opioid-induced-constipation-300279579.html http://www.prnewswire.com/news-releases/shionogi-announces-acceptance-of-new-drug-application-in-the-us-for-naldemedine-for-the-treatment-of-opioid-induced-constipation-300279579.html http://www.prnewswire.com/news-releases/shionogi-announces-acceptance-of-new-drug-application-in-the-us-for-naldemedine-for-the-treatment-of-opioid-induced-constipation-300279579.html http://www.prnewswire.com/news-releases/shionogi-announces-acceptance-of-new-drug-application-in-the-us-for-naldemedine-for-the-treatment-of-opioid-induced-constipation-300279579.html

Table of Contents for the Digital Edition of Hospital Pharmacy - July/August 2017